The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Prediction of systemic fungal infection in allogeneic marrow recipients: impact of amphotericin prophylaxis in high-risk patients.
Abstract
PURPOSE: To identify risk factors that might predict for systemic fungal infections in marrow transplant recipients within the first 100 days and to assess the efficacy of low-dose amphotericin B used as prophylaxis for candidemia and infection with invasive Aspergillus species in patients at risk. PATIENTS AND METHODS: A retrospective analysis of transplant outcomes for 331 allogeneic marrow recipients transplanted between 1983 and 1989 was performed to identify patients who might be at increased risk of fungal infection. Factors analyzed included disease, remission status, transplant regimen, graft-versus-host disease (GVHD) prophylaxis, duration of neutropenia, and development of GVHD. A trial of low-dose amphotericin (5 to 10 mg/d) begun on day +1 and continuing for 2 to 3 months posttransplant was begun in 1987 to evaluate its utility in reducing systemic mycoses. RESULTS: There were 18 episodes of candidemia and 18 systemic mycoses documented by blood or tissue culture or by biopsy. The initiation of high-dose (0.5 to 1 mg/kg/d) corticosteroids early as a component of GVHD prophylaxis in 1986 was identified as the most important risk factor for fungal infections, with a sixfold increase in infections as compared with the previous GVHD regimen (P < .0001); this was despite a significant decrease in the incidence of grade II to IV GVHD (7% v 43%; P = .0001). Low-dose amphotericin B initiated before the start of high-dose corticosteroid GVHD prophylaxis reduced the incidence of fungal infections from 30% to 9% (P = .01) without renal toxicity. Cyclosporine levels were lower in the patients who received amphotericin, leading to an increase in the rate of GVHD to 19% (P = .02). Controlling for GVHD prophylaxis, prolonged neutropenia (P = .00), and grade II to IV GVHD (P = .01) were also identified as risk factors for fungal infection. CONCLUSION: Amphotericin B can be used in low doses as prophylaxis for fungal infections early in the posttransplant course. However, cyclosporine doses need to be monitored to maintain target levels.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Van t Wout, J. W., Mattie, H., & van Furth, R. (1989) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.33.2.147 · Cited by 72
Cited by
Aspergillus fumigatus and Aspergillosis
Latgé, J.-P. (1999) · Clinical Microbiology Reviews · doi:10.1128/cmr.12.2.310 · Cited by 2,307
Therapeutic Outcome in Invasive Aspergillosis
Denning, D. W. (1996) · Clinical Infectious Diseases · doi:10.1093/clinids/23.3.608 · Cited by 689
Glucocorticoids and invasive fungal infections
Lionakis, M. S., & Kontoyiannis, D. P. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14904-5 · Cited by 669
(2000) · Biology of Blood and Marrow Transplantation · doi:10.1016/s1083-8791(00)70002-4 · Cited by 607
Aspergillus Infections in Transplant Recipients
Singh, N., & Paterson, D. L. (2005) · Clinical Microbiology Reviews · doi:10.1128/cmr.18.1.44-69.2005 · Cited by 579
Metadata
- Authors
- O'Donnell, M. R., Schmidt, G. M., Tegtmeier, B. R., Faucett, C., Fahey, J. L., Ito, J., Nademanee, A., Niland, J., Parker, P., & Smith, E. P.
- Venue
- Journal of Clinical Oncology
- Published
- 1994-04
- Volume
- 12
- Issue
- 4
- Pages
- 827-834
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1908814744
- Cited by
- 158
- References
- 1
- FWCI
- 13.44
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Prediction of systemic fungal infection in allogeneic marrow recipients: impact of amphotericin prophylaxis in high-risk patients. https://app.cochat.ai/papers/10.1200/jco.1994.12.4.827
- The paper
- O'Donnell, M. R., Schmidt, G. M., Tegtmeier, B. R., Faucett, C., Fahey, J. L., Ito, J., Nademanee, A., Niland, J., Parker, P., & Smith, E. P. (1994). Prediction of systemic fungal infection in allogeneic marrow recipients: impact of amphotericin prophylaxis in high-risk patients. Journal of Clinical Oncology. https://doi.org/10.1200/jco.1994.12.4.827
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.